ABSTRACT
Genetic variations in cytochrome P450 2C19 (CYP2C19) contribute to interindividual variability in the metabolism of therapeutic agents such as clopidogrel. Polymorphisms in CYP2C19 are associated with large interindividual variations in the therapeutic efficacy of clopidogrel. This study evaluated the in vitro oxidation of clopidogrel by 21 CYP2C19 variants harboring amino acid substitutions. These CYP2C19 variants were heterologously expressed in COS-7 cells, and the kinetic parameters of clopidogrel 2-oxidation were estimated. Among the 21 CYP2C19 variants, 12 (that is, CYP2C19.5A, CYP2C19.5B, CYP2C19.6, CYP2C19.8, CYP2C19.9, CYP2C19.10, CYP2C19.14, CYP2C19.16, CYP2C19.19, CYP2C19.22, CYP2C19.24 and CYP2C19.25) showed no or markedly low activity compared with the wild-type protein CYP2C19.1B. This comprehensive in vitro assessment provided insights into the specific metabolic activities of CYP2C19 proteins encoded by variant alleles, and this may to be valuable when interpreting the results of in vivo studies.
Subject(s)
Alleles , Cytochrome P-450 CYP2C19/genetics , Genetic Variation/physiology , Ticlopidine/analogs & derivatives , Animals , COS Cells , Chlorocebus aethiops , Clopidogrel , Genetic Variation/drug effects , Humans , Liver/drug effects , Liver/enzymology , Oxidation-Reduction/drug effects , Ticlopidine/metabolism , Ticlopidine/pharmacologyABSTRACT
Metrifonate is an organophosphorous compound that has been used in the treatment of schistosomiasis. In this study, we investigated the effects of metrifonate on the impairment of learning and on central cholinergic dysfunction in scopolamine-treated and basal forebrain-lesioned rats. Oral administration of metrifonate (5.0-15.0 mg/kg) ameliorated the scopolamine- and basal forebrain. lesion-induced learning impairment in the water maze and passive avoidance tasks. Metrifonate (50 and 100 mg/kg) also significantly increased extracellular acetylcholine levels but decreased choline levels in the cerebral cortex of the basal forebrain-lesioned rats. The basal forebrain lesion decreased the cholinesterase activity in the cerebral cortex, and metrifonate (100 mg/kg) further reduced the cholinesterase activity. However, cholinesterase inhibition was not observed at the dose that ameliorated learning impairments. These results indicated that metrifonate ameliorated the impairment of learning in both scopolamine-treated and basal forebrain-lesioned rats by not only increasing extracellular acetylcholine levels by inhibiting cholinesterase, but also by undefined other mechanism(s). This finding suggests the usefulness of metrifonate for the therapy of Alzheimer's disease.
Subject(s)
Autonomic Nervous System Diseases/drug therapy , Cholinesterase Inhibitors/therapeutic use , Memory Disorders/drug therapy , Sympathetic Nervous System/drug effects , Trichlorfon/therapeutic use , Acetylcholine/metabolism , Amnesia/drug therapy , Animals , Autonomic Nervous System Diseases/chemically induced , Autonomic Nervous System Diseases/psychology , Avoidance Learning/drug effects , Brain/enzymology , Cholinergic Antagonists , Cholinesterases/metabolism , Learning/drug effects , Male , Maze Learning/drug effects , Memory Disorders/psychology , Microdialysis , Prosencephalon/pathology , Rats , Rats, Wistar , Scopolamine , Sympathetic Nervous System/metabolismABSTRACT
Interest has recently focused on tobacco and/or nicotine in relation to senile dementia of the Alzheimer type because the population of patients with this disease among tobacco smokers is significantly smaller than in nonsmokers. We investigated whether, in relation to the dopaminergic neuronal system, nicotine was effective in ameliorating the impairment of performance in passive avoidance tasks in rats induced by scopolamine, an inhibitor of muscarinic acetylcholine receptors. Scopolamine and nicotine were coadministered to rats 30 min before the acquisition trial. Some rats received scopolamine alone; they showed much shorter step-through latency (STL) than the control group in the retention test. Nicotine significantly prolonged the decreased STL induced by scopolamine. The effects of nicotine were inhibited by the preadministration of mecamylamine, SCH 23390, and (-)sulpiride, which are nicotinic acetylcholine, D1, and D2 receptor antagonists, respectively. These results suggest that nicotine, by activating the nicotinic acetylcholinergic and dopaminergic neuronal systems, ameliorates the impairment of performance in the passive avoidance task induced by a muscarinic acetylcholine receptor blocker.
Subject(s)
Avoidance Learning/drug effects , Dopamine/physiology , Neurons/physiology , Nicotine/pharmacology , Scopolamine/antagonists & inhibitors , Animals , Benzazepines/pharmacology , Dopamine D2 Receptor Antagonists , Male , Mecamylamine/pharmacology , Neurons/drug effects , Nicotine/antagonists & inhibitors , Rats , Rats, Wistar , Receptors, Dopamine D1/antagonists & inhibitors , Scopolamine/pharmacology , Sulpiride/pharmacologyABSTRACT
Using the isolated perfused heart preparation supported by a donor the effects of vasodilators on the large conductance artery were studied and were compared with those on the small resistive artery and arterioles. Nitroglycerin produced a preferential dilation of the large conductance artery, while dipyridamole produced a dilation only of the small resistive artery and arterioles. Among the "calcium antagonistic" vasodilators tested, only diltiazem produced a dilatation of the large conductance artery, verapamil and nifedipine producing a dilatation only of the small resistive artery and arterioles. These findings indicate that the mechanism of contraction of the large conductance artery is different from that of the small resistive artery and arterioles.
